MiNK Therapeutics (INKT) Other Non Operating Income (2020 - 2026)
MiNK Therapeutics (INKT) posted Other Non Operating Income of $58585.0 for Q1 2026, up 799.94% sequentially from -$8370.0 in Q4 2025, and up 173.67% YoY from $21407.4 in Q1 2025.
MiNK Therapeutics (INKT) Other Non Operating Income (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Other Non Operating Income for 7 years, with the latest figure at $58585.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 173.67% year-over-year to $58585.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104949.0 (down 58.28% YoY) and the FY2025 annual result came in at -$32370.0, down 109.78% from the prior year.
- Other Non Operating Income rose to $58585.0 in Q1 2026 per INKT's latest filing, from -$8370.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $1.6 million in Q3 2022 and troughed at -$401964.0 in Q1 2022.
- A 5-year average of $235479.9 and a median of $8.0 in 2023 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income jumped 1795.43% in 2022, then tumbled 9947.06% in 2025.
- Over 5 years, Other Non Operating Income stood at -$15365.0 in 2022, then soared by 99.88% to -$18.0 in 2023, then surged by 572.22% to $85.0 in 2024, then sank by 9947.06% to -$8370.0 in 2025, then soared by 799.94% to $58585.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $58585.0, -$8370.0, and $240734.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16,000.00 |
| Mar 31, 2026 | 58,585.00 |
| Dec 31, 2025 | -8,370.00 |
| Sep 30, 2025 | 240,734.00 |
| Jun 30, 2025 | -186,000.00 |
| Mar 31, 2025 | -79,527.00 |
| Dec 31, 2024 | 85.00 |
| Jun 30, 2024 | 331,000.00 |
| Dec 31, 2023 | -18.00 |
| Sep 30, 2023 | 8.00 |
| Dec 31, 2022 | -15,365.00 |
| Sep 30, 2022 | 1.56 Mn |
| Jun 30, 2022 | 1.56 Mn |
| Mar 31, 2022 | -401,964.00 |
| Dec 31, 2021 | 598,739.00 |
| Sep 30, 2021 | -364,844.00 |
| Jun 30, 2021 | 82,267.00 |
| Mar 31, 2021 | -94,243.00 |
| Dec 31, 2020 | 676,301.00 |
| Sep 30, 2020 | 519,878.00 |